Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

AJ Bell upbeat on strong second-quarter performance

(Sharecast News) - Investment platform AJ Bell reported a robust performance across its platform business and AJ Bell Investments in a second quarter update on Thursday. The FTSE 250 company said that in its platform business segment, customer numbers surged 19,000 during the three months ended 31 March, surpassing the half-million milestone to close at 503,000, representing an 11% increase over the year and a 4% increase during the quarter.

Notably, total advised customers increased 8% year-on-year, reaching 165,000, while total direct-to-consumer (D2C) customers increased 12% to 338,000.

The firm said it also achieved record assets under administration (AUA) of £80.3bn, marking a 17% increase over the last year and a 5% increase during the quarter.#

Gross and net inflows across the platform experienced significant growth in the run-up to the tax-year-end, with gross inflows reaching £3.4bn, up 36% compared to the prior year, and net inflows totaling £1.6bn, up 33% versus the prior year.

The company said favourable market movements also contributed to that growth, adding 3% in the quarter.

In AJ Bell Investments, assets under management (AUM) surged to £5.8bn, representing a 49% increase over the past year and a 12% increase during the quarter.

Net inflows in the quarter totalled £0.4bn.

"Surpassing half a million platform customers is a significant milestone for the business which reflects the continued success of our dual-channel model," said chief executive officer Michael Summersgill.

"Having listed in 2018 with just under 200,000 platform customers, this landmark demonstrates the strong execution of our organic growth strategy set out at IPO.

"We remain committed to providing low-cost, easy-to-use products that can be trusted by customers and advisers, and our continued investment into our customer propositions puts us in an excellent position to deliver further strong organic growth in the future."

Summersgill said the company was "excited" about the upcoming launch of its "ready-made" pension service, which he said would help customers to consolidate their existing pensions with AJ Bell and invest them automatically via its low-cost, in-house investment solutions.

"Looking further ahead, the growth opportunity for the platform market remains significant and our ongoing brand investment will continue to drive increased awareness of AJ Bell, supporting our long-term growth ambitions."

AJ Bell said it would announce its interim results for the six months ended 31 March on 23 May.

At 0829 BST, shares in AJ Bell were up 6.61% at 314.5p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

Distil makes inaugural distillation of Blackwood at Ardgowan
(Sharecast News) - Premium drinks group Distil announced a significant milestone on Tuesday, with the successful inaugural distillation of 'Blackwood' at Ardgowan Distillery.
OptiBiotix Health inks manufacturing deal with KAG Industries
(Sharecast News) - Life sciences company OptiBiotix Health announced on Tuesday that its its Indian subsidiary, OptiBiotix Health India (OHI), has entered into a manufacturing agreement with KAG Industries for the supply of 'Slimbiome' products tailored for the Indian market.
Pebble Group maintains consistent trading in year to date
(Sharecast News) - Promotional products commerce and services specialist the Pebble Group said in a trading update on Tuesday that in the year to date, it had maintained a financial performance consistent with the same period in 2023.
Poolbeg agrees 12-month option over potential Behcet's treatment
(Sharecast News) - Poolbeg Pharma announced an exclusive 12-month option agreement with Silk Road Therapeutics on Tuesday, to potentially acquire a novel topical muco-adherent formulation of Pentoxifylline (tPTX).

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.